Back to Trades
Sell4
Kiniksa Pharmaceuticals International, plc
KNSA
Total Value
$2.6M
Net $1.8M sold
Sales
$1.8M
3 transactions
Company Information
- Company Name
- Kiniksa Pharmaceuticals International, plc
- Ticker Symbol
- KNSA
- CIK
- 0001730430
Insider Information
- Name
- Paolini John F.
- Role
- Insider
- Location
- LONDON, X0
Filing Details
- Filing Date
- Mar 4, 2026
- Transaction Date
- Mar 2, 2026
- Accession Number
- 0001741533-26-000002
- Form Type
- 4
- Net Trading Amount
- -$1.8M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Class A Ordinary Share | 40,000 | $10.36 | Exercise | $414.4K |
| Mar 2, 2026 | Class A Ordinary Share | 12,063 | $44.20 | Sale | $533.2K |
| Mar 2, 2026 | Class A Ordinary Share | 22,223 | $44.88 | Sale | $997.4K |
| Mar 2, 2026 | Class A Ordinary Share | 5,714 | $45.92 | Sale | $262.4K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Derivative | 40,000 | $10.36 | Exercise | $414.4K |
Footnotes
- (F1)This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.
- (F2)This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.555 and $44.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- (F3)This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.555 and $45.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- (F4)This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.56 and $46.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- (F5)The option is fully vested and exercisable.